Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest Phenols Stories

2014-04-16 23:16:46

Passages Malibu issues statement on the ongoing problem with prescription opioids in the US. Malibu, CA (PRWEB) April 16, 2014 A three-year study of prescription painkillers published March 3rd in the JAMA Internal Medicine revealed that individuals with the highest risk for overdose obtain medication from a doctor’s prescription. The use of opioid painkillers for non-medical reasons has grown substantially over the last decade. Some of the prescription opioids that are misused include...

2014-04-16 16:30:50

DUBLIN, April 16, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/q7jzmk/sustained_release) has announced the addition of the "Concise Analysis of International Sustained Release Injectables to 2020" [http://www.researchandmarkets.com/research/q7jzmk/sustained_release ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Formulations, Dosing, Devices, Markets and Forecasts The ability...

2014-04-15 16:28:26

SAN DIEGO, April 15, 2014 /PRNewswire/ -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the U.S. District Court in Massachusetts entered an order, preventing the implementation of the Commonwealth's ban of Zohydro(TM) ER on Constitutional grounds. This order will become effective on April 22, 2014. The court decision today supports the...

2014-04-11 08:24:52

SAN DIEGO, April 11, 2014 /PRNewswire/ -- Rampant misinformation about Zohydro(TM) ER continues to be reported by the media and echoed in Washington D.C. and some states' capitals. These inaccurate and misleading statements are often made without proper context, and are intended to be sensational, to create fear, or to generate headlines. In many instances, these statements are not supported by scientific facts or medical evidence. Let's get the facts straight Zohydro ER is the first and...

2014-04-09 08:28:45

PORTLAND, Ore., April 9, 2014 /PRNewswire/ -- Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, received FDA approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10%, to dilate the pupil on March 21, 2013. There is no longer a need to continue using unapproved versions of Phenylephrine Hydrochloride Ophthalmic Solution, as Paragon BioTeck's FDA approved Phenylephrine...

2014-04-09 08:28:15

SANTA ROSA, Calif., April 9, 2014 /PRNewswire/ -- A new study shows that honokiol, a small molecule polyphenol extract derived from Magnolia officinalis bark, reduces proliferation of renal cell carcinoma. Conducted by researchers at the Cancer Research Laboratory at Indiana University Health, Indiana University School of Medicine, the preclinical study showed that honokiol (HonoPure®, EcoNugenics, Santa Rosa, CA) inhibited two highly aggressive renal cell carcinoma (RCC) cell lines....

2014-04-08 20:21:36

SAN DIEGO, April 8, 2014 /PRNewswire/ -- Today Zogenix presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the U.S. Food and Drug Administration (FDA)-approved prescription drug product, Zohydro(TM) ER (hydrocodone bitartrate) extended-release capsules (CII), entered on March 27, 2014, by Massachusetts Governor Deval Patrick. Zogenix appreciates the opportunity to be heard by the court on an expedited basis. A follow-up hearing has been...

2014-04-07 16:25:34

Company Files for Injunction - Prescription Drug Status Should Reside Solely With the FDA SAN DIEGO, April 7, 2014 /PRNewswire/ -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today filed a lawsuit in the U.S. District Court in Massachusetts requesting the court to grant a temporary restraining order against execution of the executive order recently announced by...

2014-04-07 12:32:56

First presentation of detailed BUNAVAIL clinical data scheduled for April 11 and 13, 2014 RALEIGH, N.C., April 7, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that data from clinical studies of BUNAVAIL will be presented at the American Society of Addiction Medicine (ASAM) 45(th) Annual Medical-Scientific Conference, April 10-13, 2014 in Orlando, Florida. Four abstracts will be presented highlighting data from the clinical development...

2014-04-07 08:30:13

RICHMOND, Va., April 7, 2014 /PRNewswire/ -- Kaleo (formerly Intelliject) today announced that it has entered into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaleo to support commercialization of EVZIO(TM)(naloxone hydrochloride injection) and development of key pipeline products. Under the financing, PDL provided $150 million in cash at closing and will receive interest on the principal outstanding. The note is backed by royalty payments on kaleo's first...